Data investigation

Newer Is Not Stronger

Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·2 citations

Survodutide is a new drug with a new mechanism, and its phase 3 results are in the New England Journal of Medicine.[1] It produced 13.0% weight loss at 76 weeks. Its higher dose caused gut side effects in nearly nine of ten participants and lost barely more weight than the lower one (13.0% against 12.2%). A newer drug is not necessarily a stronger one. Drugs still in development are harder still to rank, because the most striking early figure among them comes from a four-week study.

What it is and what it did

Survodutide activates the GLP-1 receptor and the glucagon receptor, a different second target from tirzepatide’s GIP. Glucagon is best known for raising blood sugar, and the rationale for stimulating it deliberately is that it also increases energy expenditure and acts on the liver. The full picture, including the diabetes trial, the liver data and heart rate, is in survodutide: what the phase 3 evidence shows.

The trial randomized 725 adults with a BMI of 30 or above, or 27 with a weight-related complication and no diabetes, to survodutide at 3.6 mg, 6.0 mg, or placebo for 76 weeks, analyzed on the conservative treatment-regimen estimand.

SYNCHRONIZE-1 at 76 weeks, treatment-regimen estimand.[1]
3.6 mg6.0 mgPlacebo
Weight change−12.2% (95% CI −13.6 to −10.8)−13.0% (−14.4 to −11.6)−5.4% (−6.9 to −4.0)
Reached at least 5% loss72.6%71.9%46.3%
Gastrointestinal adverse events80.9%89.7%47.9%

No deaths occurred, and all comparisons against placebo reached P<0.001.

Two doses, one result, different costs

Going from 3.6 mg to 6.0 mg bought 0.8 percentage points of weight loss and raised gastrointestinal side effects from 80.9% to 89.7%. The proportion reaching a 5% reduction went down, from 72.6% to 71.9%. On weight, the higher dose roughly matched the lower one, with more people feeling sick.

A second phase 3 trial, in 752 adults who also had type 2 diabetes, has since been published. At 76 weeks the two doses produced −8.2% and −9.8% against −3.9% on placebo, and gastrointestinal adverse events rose from 72.8% to 77.7% with the higher dose, against 38.6% on placebo.[2] The two trials enrolled different people, so their headline numbers do not compare with each other. What repeats is the pattern inside each one: a small step between doses, paid for in side effects.

That is the same pattern we found in a trial of a different drug, where tripling the dose produced no additional blood sugar benefit (see the dose that stopped helping). Dose-response curves flatten, and they flatten on efficacy before they flatten on harm.

Read the placebo column before the headline

The placebo group lost 5.4%, and 46.3% of them reached a 5% reduction. That is a large placebo response: nearly half of people receiving no active drug hit the threshold the trial was built around.

The drug’s own contribution is about 7.6 percentage points, not 13.

Everyone in the trial received counseling for lifestyle modification, and 76 weeks of structured attention produces real weight loss on its own. Quoting −13.0% without the placebo arm hides that about 40% of it (5.4 points) also happened on placebo, and that is the number that will circulate.

The comparison we are not going to make

It is tempting to set −13.0% against semaglutide’s familiar figures and tirzepatide’s, and conclude the new drug is weaker. That is a cross-trial comparison, and it is the move this register criticizes when sellers make it. The trials differ in participants, placebo arms, durations and estimands.

There is one place a fair comparison exists. A network meta-analysis of 262 trials places every drug against a common reference, which is what makes them comparable (see what 262 trials say together). That analysis is where a ranking belongs, not here.

What can be said from this trial alone: survodutide works, it works substantially better than placebo, and the higher of its two doses adds side effects while adding little weight loss.

Why it is still worth watching

  • The mechanism is new. Glucagon receptor agonism is not GIP, and its effects on the liver and on energy expenditure may show up on endpoints this trial did not measure.
  • Weight is not the only outcome that matters. The drug with the most weight loss is not the drug with the mortality evidence, which is set out in the head-to-head.
  • It is unapproved. No label, no manufacturer of record, and peptide sellers are already marketing it. FDA has warned some of them, following the pattern documented in retatrutide’s phase 3 and the gray market.
  • Funded by Boehringer Ingelheim, which is developing it.

Frequently Asked Questions

In its phase 3 trial in adults without diabetes, 12.2% at 3.6 mg and 13.0% at 6.0 mg over 76 weeks, against 5.4% on placebo. The drug's own contribution over placebo is therefore about 7.6 percentage points. In a second phase 3 trial in adults with type 2 diabetes, the figures were 8.2% and 9.8% against 3.9% on placebo.
Not meaningfully. It produced 0.8 percentage points more weight loss, a slightly lower proportion reaching a 5% reduction, and gastrointestinal side effects in 89.7% of participants against 80.9%.
Not from this trial. Comparing across separate trials with different participants and placebo arms is not a comparison. A network meta-analysis of 262 trials is where each drug is placed against a common reference.
It activates the glucagon receptor alongside the GLP-1 receptor, a different second target from tirzepatide's GIP. Glucagon raises energy expenditure and acts on the liver, so the drug may show effects on endpoints this trial did not measure.
No. It is investigational, with no approval, no label and no legal route to a pharmacy.

References

  1. 1.le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity The New England Journal of Medicine. 2026. PMID: 42253238.
  2. 2.Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes The New England Journal of Medicine. 2026. PMID: 42820639.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →